1. Introduction {#s0005}
===============

The insulin receptor is a membrane protein composed of two extracellular α subunits that bind insulin and two β subunits which span the plasma membrane and have an intracellular tyrosine kinase domain [@bb0005], [@bb0010]. Insulin binding to the α-subunits causes a conformational change that results in the activation of the kinase activity of the β-subunits with subsequent autophosphorylation and activation of kinase activity toward intracellular substrates [@bb0005], [@bb0010]. A single gene codes for both subunits. The resulting preprotein is post-translationally cleaved into mature alpha and beta subunits that assemble together as a heterotetramer to generate the mature insulin receptor [@bb0005], [@bb0010], [@bb0015]. The *INSR* gene maps to the short arm of chromosome 19 and is composed of 22 exons. Alternative splicing of the 36 base pair exon 11 results in two isoforms which differ in sequence at the C-terminal end of the insulin-binding alpha-subunit [@bb0015].

Mutations in *INSR* cause the insulin-resistant syndromes Leprechaunism, also known as Donohue syndrome [@bb0020], Rabson--Mendenhall syndrome and type A insulin resistance [@bb0025], [@bb0030]. Leprechaunism, (OMIM [246200](246200){#ir0045}), the most severe of the insulin resistant syndromes, is characterized by intrauterine growth restriction (IUGR), loss of glucose homeostasis, hyperinsulinemia, and dysmorphic features, with prominent eyes, thick lips, upturned nostrils, low-set posteriorly rotated ears, thick skin with lack of subcutaneous fat, distended abdomen, and enlarged genitalia in the male and cystic ovaries in the female [@bb0035], [@bb0040], [@bb0045]. Cells from most patients with Leprechaunism have markedly reduced insulin binding, although exceptions were reported [@bb0050], [@bb0055].

The slightly less severe Rabson--Mendenhall syndrome (OMIM [262190](262190){#ir0050}) was first described in three siblings with dental and skin abnormalities, abdominal distension, phallic enlargement, early dentition, coarse senile-looking facies, striking hirsutism, intellectual disability, prognathism, thick fingernails and acanthosis nigricans. Insulin-resistant diabetes mellitus, ketoacidosis, intercurrent infections, pineal hyperplasia and ovarian tumor [@bb0060]. Children have initial postprandial hyperglycemia and fasting hypoglycemia, caused by inappropriately elevated insulin levels at the time of fasting [@bb0030], [@bb0065]. Patients with Rabson--Mendenhall syndrome can survive beyond 1 year of age and, with time, develop constant hyperglycemia followed by diabetic ketoacidosis and death. This is accompanied by a progressive decline of insulin levels, which become insufficient to prevent liver glucose synthesis and release of fatty acids by adipocytes [@bb0065].

Mutations in the insulin receptor can cause disease with a dominant pattern of inheritance as well. For example, a mutation (p.Gly996Val) in a conserved Gly-X-Gly-X-X-Gly motif impairs tyrosine kinase activity of the insulin receptor and is associated with insulin-resistant diabetes mellitus and acanthosis nigricans, suggesting a dominant-negative pathogenesis [@bb0070], [@bb0075], [@bb0080]. A different mutation (p.Arg1174Gln) with unknown functional effects in *INSR* is implicated in familial hyperinsulinemic hypoglycemia type 5 in a few patients (HHF5) [@bb0085].

Leprechaunism and Rabson--Mendenhall syndrome are inherited as autosomal recessive traits. There is some correlation between genotype and phenotype, with mutations that markedly impair insulin binding resulting in the most severe phenotypes, while the presence of at least one mutation leaving residual insulin binding activity is associated with longer survival [@bb0030], [@bb0090]. Definitive genotype--phenotype correlation for *INSR* defects is difficult to establish primarily due to the rarity of these syndromes [@bb0030], a paucity of functional studies to determine the effect of mutations on insulin binding or signaling, and difficulty in establishing a precise molecular diagnosis due to the lack of clinically validated *INSR* gene sequencing [@bb0030], [@bb0095].

Herein we develop a clinically validated sequencing method to discover mutations in the *INSR* gene. Bidirectional sequencing with BigDye terminator and M13 primers was used to examine mutations in the coding regions and exon--intron boundaries of the *INSR* gene. A combination of the biochemical and DNA tests can provide accurate diagnosis for the insulin receptor deficiency.

2. Materials and methods {#s0010}
========================

2.1. Patients/samples {#s0025}
---------------------

DNA from 11 unrelated individuals (7 controls and 4 patients with Leprechaunism) was used to determine performance characteristics of this *INSR* full gene sequencing assay. Of these four patients with Leprechaunism, three of them, referred to here as 452, NY1, and 5880, had previously been described [@bb0030], [@bb0035], [@bb0115] Fibroblasts from each of these patients were received and DNA was extracted by MagNA Pure. The fourth patient with Leprechaunism, SLC, was not previously described but fit the clinical criteria. The diagnosis of Leprechaunism for all four patients was established from clinical presentation (failure to thrive, growth retardation, markedly elevated insulin levels, hirsutism, and acanthosis nigricans) and markedly reduced insulin binding to patients\' fibroblasts. The samples were de-identified following an Institutional Review Board (IRB)-approved protocol. Fourteen additional samples referred to the ARUP Sequencing Laboratory by the patients\' clinicians for *INSR* mutation detection were sequenced and analyzed.

2.2. DNA sequencing of the *INSR* gene {#s0030}
--------------------------------------

DNA was extracted from leukocytes in blood using MagNAPure Compact instrument (Roche Applied Science, Indianapolis, IN). Nucleic acid sequencing for the *INSR* gene coding region was performed by standard dideoxy termination. PCR primers were developed for the 22 exons of the *INSR* isoform containing exon 11 ([NM_002082](ncbi-n:NM_002082){#ir0055}). Eighteen sets of PCR primers used in this validation were previously published [@bb0100], however, in the current study four sets of primers were re-designed to optimize PCR and sequencing results (see [Table 1](#t0005){ref-type="table"}). We added another internal primer set to exon three interior to the homopolymer region to obtain cleaner sequence. In addition, exons 18 and 19 were consolidated into one amplicon. polymerase chain reaction of the 22 coding exons of the *INSR* gene was performed using M13-tailed primers Premix D (Epicentre, Madison, WI), and Platinum Taq (Invitrogen, Carlsbad, CA) using PCR conditions shown in [Table 2](#t0010){ref-type="table"} below. Unused PCR primers and unincorporated nucleotides were inactivated by incubation with ExoSAP (USB Corporation, Cleveland, OH). Bidirectional DNA sequencing was performed with BigDye Terminator chemistry (ABI, Foster City, CA) and M13 primers (IDT, Coralville, IA) and the product was analyzed on the ABI 3730. Data analysis was performed using Mutation Surveyor software (SoftGenetics, State College, PA) and GenBank reference sequence [NG_008852.1](ncbi-n:NG_008852.1){#ir0060}.

3. Results {#s0015}
==========

3.1. *INSR* mutation update {#s0035}
---------------------------

The *INSR* gene product contains 120 kilobases and is composed of 22 exons. There are three transcription initiation sites located at 276, 282 and 283 base pairs upstream of the translation initiation site. The alpha subunit is encoded by exons one through 11 (and part of exon 12) whereas the beta subunit is encoded by exons 12--22 [@bb0005], [@bb0010]. The insulin receptor is synthesized as a single protein that is post-translationally cleaved at a four amino acid site (p.759_762, RKRR, encoded by exon 12) to generate the mature alpha and beta subunit.

The *INSR* gene product contains a leader sequence of 27 amino acids. Cleavage of these amino acids results in the mature active protein. As a result of this cleavage, the nomenclature of reported variations differs depending on the author, time of publication, and source of their reference DNA sequence. For this reason, we reviewed the published literature for all known *INSR* variations to determine the consistent amino acid position using the current nomenclature, in both the immature and the mature protein. Absolute nucleotide positions were kept consistent with the beginning of the cDNA regardless of protein cleavage (recommendations of the Human Genome Variation Society, <http://www.hgvs.org/rec.html>). In addition, the *INSR* gene has two isoforms that differ only by the 12 amino acids encoded by the alternatively spliced exon 11. These isoforms have slightly different reported biological activity and different abundance in different tissues with the isoform containing exon 11 being predominant in the liver; the other in leukocytes; with similar expression levels in most other tissues such as skeletal muscle, placenta and adipose tissue [@bb0105].

To date, there are 132 reports of disease causing mutations in the *INSR* gene in the literature ([Table 4](#t0020){ref-type="table"}). The majority of the mutations (64%, or 85 of 132) are missense mutations, 13% (17 of 132) are nonsense mutation, 4.7% are splice site mutations, 8.3% are deletions (11/132), 2.3% are insertions (3/132), 1.5% are insertions and deletions (indel, 2/132), 5.3% are gross deletions or complex gene rearrangements (7/132) ([Fig. 1](#f0005){ref-type="fig"}). Most of the mutations located in the first 11 exons result in Leprechaunism while the mutations in the beta subunit are found more frequently in patients with Rabson--Mendenhall syndrome.

3.2. Sequencing *INSR* {#s0040}
----------------------

Four patients with known mutations were verified by the above sequencing protocol. The first patient, NY1, with clinically-confirmed Leprechaunism [@bb0030], [@bb0110], had a homozygous G to T variation at nucleotide 451 converting Glu 151 to a premature stop codon (c.451G \> T,p.Glu151term). The second patient, 452, was a female infant with symptoms including repeated transient hypoglycemic episodes, prominent female genitalia, marked hirsutism, breast hyperplasia, loose and pachydermatous skin, decreased adipose tissue, acanthosis nigricans, and abdominal distention [@bb0035]. Sequencing results showed a heterozygous C to T nucleotide change at position 1195 coding for a premature stop codon at amino acid position 399 (c.1195C \> T, p.Arg399term). A second mutation could not be detected by the assay as in the initial publication [@bb0035]. The third patient, 5880, had physical features of Leprechaunism and his lymphoblasts had a 90% decrease in the number of insulin receptors. This patient had a heterozygous C to T nucleotide change at position 2734 resulting in a change of arginine 924 to a premature stop codon (c.2770C \> T, p.Arg924term) [@bb0115]. A second mutation could not be found even in this patient as in the original manuscript [@bb0120].

The forth patient, SLC, died before one year of age and had physical features of Leprechaunism. Insulin binding was reduced to about 4% of normal in fibroblasts from this patient. A novel G to T missense mutation was identified at nucleotide position 425 resulting in a change of glycine 142 to a valine (c.425G \> T, p.Gly142Val). Computational prediction with the program Polyphen 2 (Harvard) predicts that a glycine to valine amino acid change at this position is "possibly damaging" with a score of 0.814 while SIFT (J Craig Venter Institute) predicts that the substitution is "damaging". A second mutation could not be identified in this patient either.

Seven additional samples from normal, healthy individuals displayed no *INSR* variants. However all samples (as well as the clinical samples above) were found to have a benign polymorphism at nucleotide position 5 changing alanine 2 to glycine (c.5C \> G, p.Ala2Gly).

An additional fourteen clinical samples (one sample from cultured amniocytes, four samples from pediatric patients and nine from adult patients) were referred to our lab for *INSR* sequencing. The clinical phenotype and laboratory results are summarized in [Table 3](#t0015){ref-type="table"}. According to patient history received by ARUP with the amniotic sample, it was previously tested for deletions and duplications using a SNP array at another laboratory and was found to have a 63 kb deletion at 19p13.2 (7,143,507-7,206,857), including deletion of several exons of the *INSR* gene. Sequencing analysis detected no additional mutations. The 13 pediatric and adult patients presented with anomalies including, intra-uterine growth restriction (IUGR), failure to thrive (FTT), dysmorphic features, distended abdomen, and acanthosis nigricans. Although the major symptom was insulin resistance, the nine oldest patients tested were disproportionately female (7:2) with gynecological symptoms including menstrual irregularities and cystic ovaries. One 16 year old male patient had a history of IUGR, FTT, dysmorphic features, and poor response to exogenous insulin. Thirteen samples had no mutation detected by Sanger sequencing in the coding regions and exon/intron boundaries. An eleven week old boy with suspected Leprechaunism was homozygous for a variant of unknown clinical significance, c.2971C \> A, p. Leu991Ile. For this patient, no positions of heterozygosity were observed in *INSR*, therefore we cannot rule out a partial or complete gene deletion. The infant was in intensive care and presented with IUGR, bilateral club feet, congenital hydrocephalus and dysmorphic features. Patient had only the right kidney and renal tubular acidosis. The patient had sporadic hypoglycemia and was noted to have glucose levels decreasing to 40 mg/dL range after 4--5 h of fasting, but given the age and size of the patient, this is of uncertain clinical significance. This patient also had elevated beta-hydroxybutyric acid of 14.1 mg/dL (reference range: 0.0--3.0) and a random insulin level of 1 μU/mL (reference range: 3--19 μU/mL). This variant (rs150114699) has been seen in the general population with a frequency of 0.4% in 1000 genomes and 0.6% in 6500 exomes in African Americans. The homozygous variant, c.2971C \> A, p. Leu991Ile, has never been reported in the literature; sequence prediction programs give conflicting results about whether this substitution is likely to be deleterious (SIFT: deleterious; PolyPhen2: benign at score: 0.442). The next residue, Y992 is a conserved phosphorylation site in a highly conserved region (DGPLGPLyASSNPEY, <http://www.phosphosite.org/siteAction.do?id=13426>). The putative amino acid change at position L991 to the branched amino acid isoleucine may result in steric hindrance and decreased transporter activity. In light of the fact that the patient has only one kidney and is hypoglycemic, sequencing of *HNF1B* in this patient may be appropriate.

4. Discussion {#s0020}
=============

Mutations in *INSR* can cause the insulin-resistant syndromes Leprechaunism, Rabson--Mendenhall syndrome, and type A insulin resistance [@bb0025], [@bb0030]. Diagnosis is established on clinical examination as well as laboratory diagnostic tests with markedly elevated insulin levels being a constant feature. Functional studies (insulin binding to cultured fibroblasts) and DNA analysis can be used for definitive confirmation, keeping in mind that certain mutations do not decrease insulin binding and that DNA analysis is still not identifying all putative mutations. Although there is no straightforward genotype--phenotype correlation, mutations affecting the alpha subunit of the receptor are associated with a more severe phenotype than the mutations affecting the beta subunit [@bb0125].

Due to the lack of a central repository of *INSR* mutations, we compiled a list of the published mutations, using currently accepted standards ([Table 4](#t0020){ref-type="table"}). Our literature search of *INSR* mutations identified 132 causative variations. The vast majority of these variations are missense and nonsense mutations (78%) ([Fig. 1](#f0005){ref-type="fig"}). Interestingly, different missense mutations in the same codon have been reported to produce different phenotypes ([Table 4](#t0020){ref-type="table"}). This highlights the need to expand the currently available databases to allow better understanding of the genotype--phenotype correlation.

There are five reports of large deletions within the *INSR* gene including an entire gene deletion [@bb0130]. Gross deletions and gene rearrangements account for about 5% of the mutations [@bb0130]. Large deletions, as in one of our patients, can be detected by CGH/SNP arrays. For this reason, development of a commercial test to detect single exon and whole gene deletions may be attractive. No commercial deletion/duplication testing is currently available in the US; however, deletion and duplication testing is offered at laboratories in the United Kingdom and Germany. A multiplex ligation dependent probe amplification (MLPA) assay could be used to detect single exon deletions in the *INSR* gene.

DNA sequencing can identify novel sequence variants of unknown clinical significance. In our study, we detected a novel c.425G \> T, p. Gly142Val affecting the insulin binding alpha subunit of the insulin receptor. The evolutionary conservation analysis by Polyphen and SIFT predicts that a glycine to valine amino acid change at this position is "possibly damaging" or "damaging" to the function of the protein. Cells from this patient (TGB) failed to bind insulin, supporting a damaging role of the identified mutation. A second mutation in this patient could not be detected indicating the limitations of the current test in detecting mutations in the deep intronic or promoter regions or deletions, duplications, and rearrangements of the gene. In fact, sequencing failed to identify the second mutation in three patients with markedly reduced insulin binding in which previous studies also failed to detect the second pathogenic change [@bb0030], [@bb0065].

An additional sample of a pediatric patient referred for possible Leprechaunism was an apparent homozygous for c.2971C \> A, p. Leu991Ile. A review of clinical data indicated normal to low insulin levels, a finding inconsistent with severe insulin resistance and indicating that the amino acid change is of unknown significance. As no positions of heterozygosity were observed in *INSR*, we cannot rule out a partial or complete gene deletion. The effect of a deletion of one copy of *INSR* in conjunction with this variant is yet to be studied.

It should be noted that only one mutation was detected in the 14 samples sent for clinical testing. This may be related to the poor clinical selection of patients whose phenotypes were inconsistent with insulin resistance but were nevertheless referred for this *INSR* mutation detection assay. More specific selection of candidate patients may enhance the utility of the assay.

Association studies show a strong correlation between single nucleotide polymorphism (SNP) in the *INSR* gene and a predisposition to type 2 diabetes [@bb0135]. An alternative isoform of exon 8 in the *INSR* gene in the Han population confers increased risk for central obesity, hypertension, glucose intolerance, hyperinsulinemia and type 2 diabetes [@bb0140], whereas variation in exon 17 is associated with insulin resistance, hyperandrogenemism and polycystic ovarian syndrome (PCOS) [@bb0145].

In conclusion, we report the development of a sequencing assay to detect mutations within the coding region and intron/exon boundaries of the *INSR* gene. Further development of deletion/duplication analysis is needed to detect deletions, duplications and large gene rearrangement of the *INSR* gene. A compilation of all the mutations reported to date using current terminology ([Table 4](#t0020){ref-type="table"}) is the first step toward development of a publicly available online mutation database for the *INSR* gene.

Funding for this study was provided by the ARUP Institute for Clinical and Experimental Pathology.
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###### 

Sequence of *INSR* primers used in the current study. Lower case letters represent the M13 tail sequence.

  Primer name   Sequence
  ------------- --------------------------------------------
  IR E1F        tgtaaaacgacggccagtCGCGCTCTGATCCGAGGAGA
  IR E1R        caggaaacagctatgaccAGGGTTCTCAGTCCACAAGC
  IR E2F \#2    tgtaaaacgacggccagtTCTTGCTTTCTGTTCATTTTC
  IR E2R \#2    caggaaacagctatgaccACGAGACACTGCTTAGAACC
  IR E3F \#2    tgtaaaacgacggccagtCAGACAGGAATTGGACAAA
  IR E3F Int    tgtaaaacgacggccagtGACCATCTGTAAGTCACACG
  IR E3R        caggaaacagctatgaccAGCAGAGACCTCACTCATAGCCAA
  IR E4F        tgtaaaacgacggccagtGCCTGAGATGTCTGAAGGAC
  IR E4R        caggaaacagctatgaccGCCACTGAACGACCATCCTA
  IR E5F        tgtaaaacgacggccagtCTCACCATGGAGAATCATGA
  IR E5R        caggaaacagctatgaccCTAATACACGAACTTCCTAG
  IR E6F \#2    tgtaaaacgacggccagtCACACCATCTTGGAGTTGTA
  IR E6R        caggaaacagctatgaccTGTAATGCACTTGAATCATGCTG
  IR E7F \#2    tgtaaaacgacggccagtTTGGTCTGAAACTACACTGAAA
  IR E7R        caggaaacagctatgaccAAACGTAGCAAGCACAGAGC
  IR E8F        tgtaaaacgacggccagtCGGTCTTGTAAGGGTAACTG
  IR E8R \#2    caggaaacagctatgaccGCCAATAACCATATCAAGGA
  IR E9F        tgtaaaacgacggccagtGCACACTGTTTCTCATGATG
  IR E9R        caggaaacagctatgaccAGAGGTGAAGCAAAGTGCAT
  IR E10F       tgtaaaacgacggccagtTGTTCAGCCGCAGAGACTTG
  IR E10R       caggaaacagctatgaccCGGTCCCTAAGTAATGACCT
  IR E11F       tgtaaaacgacggccagtGTGGTCTGTCTAATGAAGTT
  IR E11R       caggaaacagctatgaccGAATTGGTGAAGCATCTGCT
  IR E12F       tgtaaaacgacggccagtTGATGGTGATGGTGTCATCATA
  IR E12R       caggaaacagctatgaccTGTCCTTGGTCAGCCTTGATGT
  IR E13F \#2   tgtaaaacgacggccagtCAATCTTGTGGGATGAGTTT
  IR E13R       caggaaacagctatgaccTACTAATAGCACAGTACCTG
  IR E14F       tgtaaaacgacggccagtTGGACACTCCCAGATGTGCA
  IR E14R       caggaaacagctatgaccACCATGCTCAGTGCTAAGCA
  IR E15F       tgtaaaacgacggccagtGTGAACTTTGTTGGAAACACATTG
  IR E15R       caggaaacagctatgaccCCTATACCTATATCAAGGCATG
  IR E16F       tgtaaaacgacggccagtTCTGCTGGTAAGGGCTGCCA
  IR E16R       caggaaacagctatgaccCTCACTCAATGGTGAAGGCA
  IR E17F       tgtaaaacgacggccagtCCAAGGATGCTGTGTAGATAAG
  IR E17R       caggaaacagctatgaccTCAGGAAAGCCAGCCCATGTC
  IR E18--19F   tgtaaaacgacggccagtGGAGAACCCTGGTGAGTC
  IR E18--19R   caggaaacagctatgaccTCCTTCTGAAATCAAACCTG
  IR E20F       tgtaaaacgacggccagtAGGTTAAGAGCGTGTGAACCT
  IR E20R       caggaaacagctatgaccGAATTCAAGCCCAGCGTCCAT
  IR E21F       tgtaaaacgacggccagtTGTTACTACTATCAACTGTC
  IR E21R       caggaaacagctatgaccACCTGTAACATACAGCATGC
  IR E22F       tgtaaaacgacggccagtACTCACCCAGGACGTGTCCTTCT
  IR E22R       caggaaacagctatgaccACCAGAGGAAAGCGAAAATG

###### 

PCR conditions used in this study.

  Temp (°C)   Rate (Δ°/cycle)   Time   Cycles
  ----------- ----------------- ------ --------
  94                            30 s   
  62          −0.5              45 s   10
  72                            1 m    
                                       
  94                            30 s   
  57                            45 s   25
  72                            5 m    

###### 

Clinical information and laboratory results for patient samples sequenced in this study.

  Patient   Age        Ethnicity                           Gender   Clinical and other findings
  --------- ---------- ----------------------------------- -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         Fetus      Asian                               NA       Reported advanced maternal age. A SNP array detected a 63 kb deletion involving deletion of exons 3--11 of the *INSR* gene: 19p13.2(7,143,507-7,206,857)x1; GRCh37/hg 19 sequencing of the coding exons ruled out second mutation
  2         11 weeks   African-American                    M        Possible IUGR, dysmorphic features, distended abdomen, can fast for only 4--5 h after which the glucose levels drop to 40 s, insulin 1 μU/mL (ref[a](#tf0005){ref-type="table-fn"} 3--19), renal tubular acidosis type 4, only one kidney, bilateral club feet, congenital hydrocephalus not requiring shunt; c.2971C \> A, p.Leu991Ile
  3         1 yr       [b](#tf0010){ref-type="table-fn"}   F        IUGR, low glucose fasting (35--67 mg/dL), seizures; previous testing found "regions of homozygosity" in *INSR* region by SNP array
  4         5 yr       Multi-ethnicity                     M        Delivered at 27 weeks and has complications of prematurity, holoprosencephaly, absence of corpus; loss of white matter on both occipital lobes, FTT, insulin 379.6 μU/mL (ref 3--17)
  5         11 yr      [c](#tf0015){ref-type="table-fn"}   F        Hypertriglyceridemia, low HDL cholesterol, high LDL cholesterol, nonalcoholic steatohepatitis, acanthosis nigricans, glucose fasting normal, insulin 70.5 μU/mL (ref 3--12)
  6         15 yr      NA                                  M        Extreme insulin resistance type A
  7         15 yr      African-American                    F        Acanthosis nigricans, amenorrhea, insulin 21 μU/mL (ref 3--19)
  8         16 yr      African-American                    M        IUGR, FTT, dysmorphic features, lack of subcutaneous fat, poor response to exogenous insulin or hyperforin
  9         21 yr      African-American                    F        Acanthosis nigricans, cystic ovaries, insulin 65.8 μU/mL (ref 2.6--24.9), severe insulin resistance, cystic ovaries. Medications: Trajenta, metformin, Depo--Provera therapy
  10        28 yr      Caucasian                           F        Cystic ovaries, glucose fasting 89 mg/dL, hx of heavy irregular periods, mental health symptoms, cystic ovaries
  11        29 yr      Asian Indian                        F        Amenorrhea, cystic ovaries
  12        30 yr      Caucasian                           F        Cystic ovaries
  13        50 yr      NA                                  F        Glucose fasting, 277 mg/dL (ref 70--99) unknown if fasting, insulin antibody 1.9 U/mL(\< 0.4), triglyceride 1302 mg/dL (ref 40--149); cholesterol 231 mg/dL (ref 120--199)
  14        66 yr      Caucasian                           F        Aggression, hyper-androgenism, gingival hyperplasia, thick skin, amenorrhea, distended abdomen, reported high fasting glucose fasting, high postprandial glucose 1501 mg/dL (ref \< 180 mg/dL)

Within normal reference range.

Patient from Haiti, ethnicity unknown.

Patient from Puerto Rico.

###### 

Compilation of reported *INSR* mutations.

  A. Missense/nonsense mutations                                                                                                                       
  -------------------------------- ---------- --------------- --------------- ------------- ---------------------------------------------------------- -------------
  Exon 1                           Nonsense   c.90C \> A      p.Tyr30Term     Tyr3Term      Rabson--Mendenhall syndrome                                [@bb0150]
  Exon 2                           Missense   c.121C \> T     p.Arg41Trp      Arg14Trp      Rabson--Mendenhall syndrome                                [@bb0155]
  Exon 2                           Missense   c\. 126C \> A   p.Asn42Lys      Asn15Lys      Leprechaunism                                              [@bb0160]
  Exon 2                           Missense   c.164T \> C     p.Val55Ala      Val28Ala      Leprechaunism                                              [@bb0165]
  Exon 2                           Missense   c.172G \> A     p.Gly58Arg      Gly31Arg      Leprechaunism                                              [@bb0170]
  Exon 2                           Missense   c.257A \> G     p.Asp86Gly      Asp59Gly      Insulin resistance                                         [@bb0175]
  Exon 2                           Missense   c.266T \> C     p.Leu89Pro      Leu62Pro      Insulin resistance                                         [@bb0175]
  Exon 2                           Missense   c.338G \> C     p.Arg113Pro     Arg86Pro      Leprechaunism                                              [@bb0040]
  Exon 2                           Nonsense   c.337C \> T     p.Arg113Term    Arg86Term     Insulin resistance                                         [@bb0180]
  Exon 2                           Missense   c.356C \> T     p.Ala119Val     Ala92Val      Leprechaunism                                              [@bb0030]
  Exon 2                           Missense   c.359T \> A     p.Leu120Gln     Leu93Gln      Insulin resistance                                         [@bb0185]
  Exon 2                           Missense   c.425G \> T     p.Gly142Val     Gly115Val     Leprechaunism                                              This report
  Exon 2                           Missense   c.433C \> T     p.Arg145Cys     Arg118Cys     Insulin resistance A                                       [@bb0190]
  Exon 2                           Missense   c.438C \> G     p.Ile146Met     Ile119Met     Insulin resistance                                         [@bb0195]
  Exon 2                           Nonsense   c.442A \> T     p.Lys148Term    Lys121Term    Leprechaunism                                              [@bb0200]
  Exon 2                           Nonsense   c.451G \> T     p.Glu151Term    Glu124Term    Leprechaunism                                              [@bb0030]
  Exon 2                           Nonsense   c.479G \> A     p.Trp160Term    Trp133Term    Insulin resistance                                         [@bb0160]
  Exon 2                           Missense   c.499G \> T     p.Val167Leu     Val140Leu     Insulin resistance A                                       [@bb0205]
  Exon 2                           Missense   c.511T \> A     p.Tyr171Asn     Tyr144Asn     Diabetes, NIDDM                                            [@bb0210]
  Exon 2                           Missense   c.515T \> G     p.Ile172Ser     Ile145Ser     Diabetes, NIDDM                                            [@bb0210]
  Exon 2                           Missense   c.557G \> T     p.Cys186Phe     Cys159Phe     Rabson--Mendenhall syndrome                                [@bb0095]
  Exon 2                           Missense   c.586T \> A     p.Cys196Ser     Cys169Ser     Diabetes, NIDDM                                            [@bb0210]
  Exon 2                           Missense   c.628T \> A     p.Trp210Arg     Trp183Arg     Diabetes, NIDDM                                            [@bb0210]
  Exon 3                           Missense   c.659C \> T     p.Pro220Leu     Pro193Leu     Leprechaunism                                              [@bb0215]
  Exon 3                           Missense   c.679G \> A     p.Gly227Ser     Gly200Ser     Diabetes, NIDDM                                            [@bb0210]
  Exon 3                           Missense   c.694G \> A     p.Gly232Ser     Gly205Ser     Diabetes, NIDDM                                            [@bb0210]
  Exon 3                           Missense   c.707A \> G     p.His236Arg     His209Arg     Leprechaunism                                              [@bb0160]
  Exon 3                           Missense   c.712G \> A     p.Glu238Lys     Glu211Lys     Rabson--Mendenhall syndrome                                [@bb0150]
  Exon 3                           Missense   c.766C \> T     p.Arg256Cys     Arg229Cys     Rabson--Mendenhall syndrome                                [@bb0095]
  Exon 3                           Missense   c.779T \> C     p.Leu260Pro     Leu233Pro     Insulin resistance                                         [@bb0220]
  Exon 3                           Missense   c.835C \> T     p.Arg279Cys     Arg252Cys     Insulin resistance                                         [@bb0225]
  Exon 3                           Missense   c.836G \> A     p.Arg279His     Arg252His     Insulin resistance                                         [@bb0185]
  Exon 3                           Missense   c.839G \> A     p.Cys280Tyr     Cys253Tyr     Insulin resistance A                                       [@bb0230]
  Exon 3                           Nonsense   c.895C \> T     p.Gln299Term    Gln272Term    Leprechaunism                                              [@bb0235]
  Exon 3                           Missense   c.902G \> A     p.Cys301Tyr     Cys274Tyr     Leprechaunism                                              [@bb0240]
  Exon 3                           Missense   c.932G \> A     p.Cys311Tyr     Cys284Tyr     Rabson--Mendenhall syndrome                                [@bb0245]
  Exon 4                           Missense   c.1049C \> T    p.Ser350Leu     Ser323Leu     Insulin resistance                                         [@bb0250]
  Exon 4                           Nonsense   c.1072C \> T    p.Arg358Term    Arg331Term    Insulin resistance                                         [@bb0255]
  Exon 4                           Nonsense   c.1114C \> T    p.Arg372Term    Arg345Term    Insulin resistance A                                       [@bb0260]
  Exon 5                           Missense   c.1156G \> A    p.Gly386Ser     Gly359Ser     Rabson--Mendenhall syndrome                                [@bb0265]
  Exon 5                           Missense   c.1177G \> A    p.Gly393Arg     Gly366Arg     Leprechaunism                                              [@bb0270]
  Exon 5                           Nonsense   c.1195C \> T    p.Arg399Term    Arg372Term    Insulin resistance                                         [@bb0275]
  Exon 5                           Missense   c.1225T \> G    p.Phe409Val     Phe382Val     Insulin resistance                                         [@bb0280]
  Exon 5                           Nonsense   c.1246C \> T    p.Arg416Term    Arg389Term    Leprechaunism                                              [@bb0285]
  Exon 6                           Missense   c.1316G \> C    p.Trp439Ser     Trp412Ser     Leprechaunism                                              [@bb0290]
  Exon 6                           Missense   c.1372A \> G    p.Asn458Asp     Asn431Asp     Insulin resistance                                         [@bb0185]
  Exon 6                           Missense   c.1459A \> G    p.Lys487Glu     Lys460Glu     Leprechaunism                                              [@bb0295]
  Exon 6                           Missense   c.1466A \> G    p.Asn489Ser     Asn462Ser     Insulin resistance                                         [@bb0160]
  Exon 8                           Missense   c.1627A \> T    p.Thr543Ser     Thr516Ser     Diabetes, NIDDM                                            [@bb0210]
  Exon 8                           Missense   c.1650G \> A    p.Ala550Ala     Ala523Ala     Association with reduced diastolic blood pressure          [@bb0300]
  Exon 9                           Missense   c.1975T \> C    p.Trp659Arg     Trp632Arg     Leprechaunism                                              [@bb0305]
  Exon 10                          Nonsense   c.2095C \> T    p.Gln699Term    Gln672Term    Leprechaunism                                              [@bb0295]
  Exon 10                          Missense   c.2201A \> C    p.Asp734Ala     Asp707Ala     Leprechaunism                                              [@bb0310]
  Exon 12                          Missense   c.2286G \> T    p.Arg762Ser     Arg735Ser     Insulin resistance                                         [@bb0315]
  Exon 12                          Nonsense   c.2437C \> T    p.Arg813Term    Arg786Term    Leprechaunism                                              [@bb0320]
  Exon 12                          Missense   c.2453A \> C    p.Tyr818Cys     Tyr791Cys     Leprechaunism                                              [@bb0325]
  Exon 13                          Missense   c.2572A \> G    p.Thr858Ala     Thr831Ala     Diabetes, NIDDM                                            [@bb0330]
  Exon 13                          Missense   c.2621C \> T    p.Pro874Leu     Pro847Leu     Leprechaunism/Rabson--Mendenhall syndrome                  [@bb0155]
  Exon 13                          Nonsense   c.2668C \> T    p.Arg890Term    Arg863Term    Leprechaunism                                              [@bb0325]
  Exon 13                          Missense   c.2669G \> C    p.Arg890Pro     Arg863Pro     Diabetes, NIDDM                                            [@bb0210]
  Exon 13                          Nonsense   c.2673T \> A    p.Tyr891Term    Tyr864Term    Insulin resistance A                                       [@bb0230]
  Exon 14                          Missense   c.2717C \> G    p.Ala906Gly     Ala879Gly     Diabetes, NIDDM                                            [@bb0210]
  Exon 14                          Nonsense   c.2770C \> T    p.Arg924Term    Arg897Term    Leprechaunism                                              [@bb0115]
  Exon 14                          Missense   c.2774T \> C    p.Ile925Thr     Ile898Thr     Leprechaunism                                              [@bb0030]
  Exon 14                          Missense   c.2776C \> T    p.Arg926Trp     Arg899Trp     Leprechaunism                                              [@bb0030]
  Exon 14                          Missense   c.2810C \> T    p.Thr937Met     Thr910Met     Leprechaunism                                              [@bb0335]
  Exon 16                          Missense   c.2971C \> A    p.Leu991Ile     Leu964Ile     Leprechaunism                                              This report
  Exon 16                          Missense   c.2989C \> A    p.Pro997Thr     Pro970Thr     Rabson--Mendenhall syndrome                                [@bb0030]
  Exon 17                          Missense   c.3034G \> A    p.Val1012Met    Val985Met     Diabetes, NIDDM                                            [@bb0340]
  Exon 17                          Missense   c.3059G \> A    p.Arg1020Gln    Arg993Gln     Insulin resistance                                         [@bb0345]
  Exon 17                          Missense   c.3067A \> T    p.Ile1023Phe    Ile996Phe     Insulin resistance                                         [@bb0350]
  Exon 17                          Nonsense   c.3079C \> T    p.Arg1027Term   Arg1000Term   Insulin resistance                                         [@bb0160]
  Exon 17                          Missense   c.3104G \> T    p.Gly1035Val    Gly1008Val    Diabetes, NIDDM                                            [@bb0070]
  Exon 17                          Missense   c.3143G \> A    p.Gly1048Asp    Gly1021Asp    Insulin resistance                                         [@bb0355]
  Exon 17                          Missense   c.3160G \> A    p.Val1054Met    Val1027Met    Leprechaunism                                              [@bb0305]
  Exon 17                          Missense   c.3164C \> T    p.Ala1055Val    Ala1028Val    Insulin resistance A                                       [@bb0205]
  Exon 17                          Missense   c.3224C \> A    p.Ala1075Asp    Ala1048Asp    Insulin resistance                                         [@bb0360]
  Exon 17                          Missense   c.3255C \> T    p.His1085His    His1058His    Association with polycystic ovary syndrome in lean women   [@bb0145]
  Exon 17                          Missense   c.3257T \> A    p.Val1086Glu    Val1059Glu    Diabetes, NIDDM                                            [@bb0210]
  Exon 18                          Missense   c.3283A \> G    p.Lys1095Glu    Lys1068Glu    Diabetes, NIDDM                                            [@bb0340]
  Exon 18                          Missense   c.3220G \> C    p.Glu1074Gln    Glu1047Gln    Rabson--Mendenhall syndrome                                [@bb0155]
  Exon 18                          Missense   c.3356G \> A    p.Arg1119Gln    Arg1092Gln    Leprechaunism                                              [@bb0055]
  Exon 18                          Missense   c.3355C \> T    p.Arg1119Trp    Arg1092Trp    Leprechaunism                                              [@bb0245]
  Exon 19                          Missense   c.3428T \> C    p.Ile1143Thr    Ile1116Thr    Rabson--Mendenhall syndrome                                [@bb0065]
  Exon 19                          Missense   c.3436G \> C    p.Gly1146Arg    Gly1119Arg    Insulin resistance                                         [@bb0355]
  Exon 19                          Missense   c.3439A \> T    p.Met1147Leu    Met1120Leu    Insulin resistance A                                       [@bb0365]
  Exon 19                          Nonsense   c.3447C \> A    p.Tyr1149Term   Tyr1122Term   Insulin resistance                                         [@bb0185]
  Exon 19                          Missense   c.3470A \> G    p.His1157Arg    His1130Arg    Insulin resistance                                         [@bb0370]
  Exon 19                          Missense   c.3471T \> A    p.His1157Gln    His1130Gln    Diabetes, NIDDM                                            [@bb0210]
  Exon 19                          Missense   c.3473G \> A    p.Arg1158Gln    Arg1131Gln    Insulin resistance                                         [@bb0375]
  Exon 19                          Missense   c.3472C \> T    p.Arg1158Trp    Arg1131Trp    Rabson--Mendenhall syndrome                                [@bb0065]
  Exon 19                          Missense   c.3481G \> A    p.Ala1161Thr    Ala1134Thr    Insulin resistance                                         [@bb0380]
  Exon 19                          Missense   c.3485C \> A    p.Ala1162Glu    Ala1135Glu    Insulin resistance                                         [@bb0385]
  Exon 20                          Missense   c.3540G \> A    p.Met1180Ile    Met1153Ile    Insulin resistance                                         [@bb0390]
  Exon 20                          Missense   c.3572G \> A    p.Arg1191Gln    Arg1164Gln    Diabetes, NIDDM                                            [@bb0395]
  Exon 20                          Missense   c.3602G \> A    p.Arg1201Gln    Arg1174Gln    Insulin resistance                                         [@bb0400]
  Exon 20                          Missense   c.3601C \> T    p.Arg1201Trp    Arg1174Trp    Leprechaunism                                              [@bb0405]
  Exon 20                          Missense   c.3614C \> T    p.Pro1205Leu    Pro1178Leu    Insulin resistance                                         [@bb0410]
  Exon 20                          Missense   c.3618G \> C    p.Glu1206Asp    Glu1179Asp    Insulin resistance                                         [@bb0415]
  Exon 20                          Missense   c.3616G \> A    p.Glu1206Lys    Glu1179Lys    Leprechaunism                                              [@bb0245]
  Exon 20                          Missense   c.3659G \> T    p.Trp1220Leu    Trp1193Leu    Insulin resistance                                         [@bb0415]
  Exon 21                          Missense   c.3680G \> C    p.Trp1227Ser    Trp1200Ser    Insulin resistance                                         [@bb0380]
  Exon 21                          Nonsense   c.3769C \> T    p.Gln1257Term   Gln1230Term   Insulin resistance A                                       [@bb0365]
  Exon 22                          Missense   c.4082A \> G    p.Tyr1361Cys    Tyr1334Cys    Diabetes, NIDDM                                            [@bb0330]
  Exon 22                          Missense   c.4133G \> A    p.Arg1378Gln    Arg1351Gln    Insulin resistance                                         [@bb0250]
                                                                                                                                                       

  B. Splice site, insertion/deletion, and large gene rearrangement mutations                                                                                                         
  ---------------------------------------------------------------------------- ---------------- ------------------------------------ ----------------------------------------------- -----------
  Intron 2                                                                     Splice site      c.1124-2A \> G                       Insulin resistance                              [@bb0335]
  Intron 5                                                                     Splice site      c.1268 + 2T \> C                     Rabson--Mendenhall syndrome                     [@bb0155]
  Intron 6                                                                     Splice site      c.1483 + 43G \> T                    Diabetes, type 2, association with              [@bb0420]
  Intron 13                                                                    Splice site      c.2682 + 1G \> A                     Leprechaunism                                   [@bb0045]
  Intron 14                                                                    Splice site      c.2842 + 1G \> A                     Insulin resistance A                            [@bb0425]
  Exon 17                                                                      Splice site      c.3258G \> A                         Fiber-type disproportion myopathy, congenital   [@bb0430]
  Intron 21                                                                    Splice site      c.3794 + 1G \> T                     Leprechaunism                                   [@bb0155]
  Intron 21                                                                    Splice site      c.3795-1G \> A                       Insulin resistance A                            [@bb0205]
  Exon 1                                                                       Deletion         c.22_31del10                         Insulin resistance                              [@bb0435]
  Exon 2                                                                       Deletion         c.404delA                            Leprechaunism                                   [@bb0235]
  Exon 2                                                                       Deletion         c.444_446delGAA                      Leprechaunism                                   [@bb0440]
  Exon 3                                                                       Deletion         c.927_929delCAA                      Leprechaunism                                   [@bb0045]
  Exon 4                                                                       Deletion         c.1084_1086delGTC                    Leprechaunism                                   [@bb0445]
  Exon 9                                                                       Deletion         c.1998_2001delTGAG                   Leprechaunism                                   [@bb0030]
  Exon 12                                                                      Deletion         c.2480_2487del8                      Insulin resistance                              [@bb0335]
  Exon 15                                                                      Deletion         c.2944_2945delAG                     Leprechaunism                                   [@bb0450]
  Exon 17                                                                      Deletion         c.3077_3079delTTC                    Insulin resistance                              [@bb0455]
  Exon 19                                                                      Deletion         c.3408delG                           Leprechaunism                                   [@bb0335]
  Intron 20                                                                    Deletion         c.3659 + 1_3659 + 3delGTG            Insulin resistance                              [@bb0460]
  Exon 3                                                                       Insertion        c.866_867ins12                       Rabson--Mendenhall syndrome                     [@bb0180]
  Exon 10                                                                      Insertion        c.2050_2051insG                      Leprechaunism                                   [@bb0030]
  Exon 10                                                                      Insertion        c.2125_2126insA                      Leprechaunism                                   [@bb0030]
  Exon 2                                                                       Large deletion   ex. 2 (c.101-652)                    Insulin resistance                              [@bb0350]
  Exon 3                                                                       Large deletion   ex. 3 (c.653-974)                    Insulin resistance                              [@bb0465]
  Exons 10--13                                                                 Large deletion   \> 12 kb incl. ex. 10-13             Leprechaunism                                   [@bb0245]
  Exon 14                                                                      Large deletion   1.2 kb incl. ex. 14                  Acanthosis nigricans                            [@bb0470]
  Full gene                                                                    Large deletion   Entire gene                          Leprechaunism                                   [@bb0130]
  Exon 13                                                                      Indel            c.2630_2642delins5                   Leprechaunism                                   [@bb0475]
  Exon 14                                                                      Indel            c.2752_2753delinsTG                  Diabetes, NIDDM                                 [@bb0210]
                                                                               Complex          Rec. *INSR*/Alu                      Acanthosis nigricans, insulin related           [@bb0480]
                                                                               Complex          Translocation t(7;19)(p15.2;p13.2)   Insulin resistance                              [@bb0485]
